WO2007110462A1 - Vacuna contra la tuberculosis - Google Patents
Vacuna contra la tuberculosis Download PDFInfo
- Publication number
- WO2007110462A1 WO2007110462A1 PCT/ES2007/070051 ES2007070051W WO2007110462A1 WO 2007110462 A1 WO2007110462 A1 WO 2007110462A1 ES 2007070051 W ES2007070051 W ES 2007070051W WO 2007110462 A1 WO2007110462 A1 WO 2007110462A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tuberculosis
- phop
- gene
- bcg
- inactivation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
Definitions
- the present invention relates to an isolated microorganism belonging to the Mycobacterium genus characterized in that it comprises the inactivation of the RvO757 gene that confers a PhoP- phenotype and the inactivation of a second gene that prevents the production of DIM (DIM- phenotype).
- the present invention comprises the use of said microorganism for the elaboration of a vaccine for the immunization or prevention of tuberculosis.
- BCG derived from M. bovis
- M. bovis is today the only vaccine in use against tuberculosis and is the most widely used vaccine worldwide.
- the initial promises were not fulfilled and, due to the results of a large number of efficacy trials, it is evident that the BCG vaccine, in its current form, is of limited use for the control of the disease, particularly in the Respiratory forms in adults from third world areas where the disease is endemic [4]. With a better knowledge of the virulence of M.
- tuberculosis tuberculosis and the models of immune responses that lead to the generation of protective immunity, it is possible to develop better vaccines than BCG.
- tuberculosis with the gene RvO757 (phoP) inactivated and a second independent mutation of phoP that prevents the synthesis of DIM, as a prototype of a single-dose live vaccine, and we demonstrate that, in addition to being more attenuated than BCG in SCID immunocompromised mice, it provided levels of protection comparable to conferred by BCG in mice and superior protection to BCG in guinea pigs.
- phoP gene RvO757
- the phoP gene together with the phoR is part of a two component system that shows a high degree of similarity with other two component systems that control the transcription of key virulence genes in intracellular pathogens. It also serves to control the expression of many other genes that are not directly involved in virulence [19].
- the elimination of virulence genes does not seem to be, per se, the only way to attenuate M. tuberculosis. It was demonstrated that an auxotrophic mutant of pantothenate of M. tuberculosis, incapable of de novo synthesis of pantothenic acid, persisted in SCID mice, without being able to cause the disease [17].
- tuberculosis of the present invention with the sum of 2 independent mutations 1.- in the synthesis of the PhoP proteins and 2.- the synthesis of DIM is more attenuated than BCG in The SCID mouse model, even when applied at a dose 10 times higher than that, as well as the greater degree of protection than BCG in the guinea pig model is particularly surprising and relevant.
- a first aspect of the invention refers to an isolated microorganism belonging to the genus Mycobacterium characterized in that it comprises the inactivation of the Rv 0757 gene (jphoP) and the inactivation of a second gene that eliminates the production of DIM (pthiocerol dimycocerosates).
- this isolated microorganism will be called the microorganism of the present invention.
- a second aspect of the present invention relates to an isolated microorganism belonging to the Mycobacterium genus characterized in that it comprises the inactivation of the Rv 0757 (phoP) gene and a second independent mutation of phoP that eliminates the production of DIM.
- said second mutation being in the Rv2930 gene (fadD26) which consists in the deletion of the fadD26 gene that is essential for the synthesis of DIM.
- a third aspect of the present invention refers to the use of the isolated microorganism of the present invention for the elaboration of a vaccine for the prevention of animal tuberculosis and even more preferably for the prevention of human tuberculosis as well as other uses that currently have the vaccines against tuberculosis in the treatment of diseases in humans such as bladder cancer.
- M.Sub.2 strain of M. tuberculosis the microorganism isolated from the strain of M. tuberculosis to which the RvO757 gene constructed from the clinical strain of M has been inactivated.
- tuberculosis MT103 by the insertion of a marker of resistance to kanamycin in the BcII site of the RvO757 gene of M. tuberculosis by homologous recombination according to the method described by Pelicic et al (1997) (Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis.
- said strain of the invention has two independent mutations in live attenuated vaccines derived from M. tuberculosis, the second independent mutation of phoP not affecting the vaccine properties derived from the inactivation of said gene.
- the second independent mutation of phoP not affecting the vaccine properties derived from the inactivation of said gene.
- BCG the current vaccine in use against tuberculosis since 1921. It is a live attenuated vaccine derived from a strain of M. bovis that after subculturing in the laboratory lost its virulence and today we know that it has more than one hundred deleted genes (5). From here on in the context of the present invention we will refer to as H37Rv a strain of pathogenic M. tuberculosis that has been sequenced and in which genes such as Rv CoIe refer to, ei al. (Ref CoIe ei 1998 Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544).
- MT103 as a clinical isolation of M. tuberculosis (Reference 15 Camacho et al.)
- strain 1A29 is used, which consists of strain MT 103 which has inactivated the Rv2930 gene (fadD26) by transposon 1096 described in ref 15 (Camacho e ⁇ al. 1999 Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature -tagged transposon mutagenesis Mol Microbio / 34: 257-267)
- SO2 + pS05 the strain of M. tuberculosis SO2 in which the mutation in RvO757 is complemented with the RvO757 gene by the transformation of a replicative plasmid with the mycobacterial phoP gene , but it is not able to complement the synthesis of DIM, its phenotype being phoP + DIM-.
- M. tuberculosis phoP- the strain of M. tuberculosis to which the RvO757 gene has been inactivated by deletion between the EcoRV-Bsp sites, its phoP phenotype being - DIM +.
- Rv2930 (fadD26) to the gene that is at the beginning of the operon responsible for the synthesis of the pthiocerol dimycocerosatos (Reference 15 Camacho et al. 1999) and the elimination of this gene in M. tuberculosis it confers a stable DIM - phenotype.
- Fig. 1 Western blot analysis. Western blot image of extracellular protein extracts of MT103, of the SO2 strain of the present invention and BCG Pasteur, using polyclonal antibodies obtained against PhoP and ESAT-6.
- the MT103 strain has an ESAT6 + and phoP + phenotype
- the SO2 strain has a PhoP- and ESAT6 + phenotype
- the BCG vaccine strain is PhoP + and ESAT6 -.
- FIG. 2 Attenuation of the SO2 strain of the present invention in SCID mice.
- the means of survival days were greater than 245 days (SO2), 62.1 + 5.88 (SO2 + pSO5) and 36.7 ⁇ 0.67 (MT 103).
- Fig. 3 Cellular immune responses in mice vaccinated with the SO2 strain of the present invention and BCG.
- Balb / c mice were vaccinated subcutaneously with 8x10 3 cfu of BCG (Phipps) or 2.5 x 10 3 cfu of the SO2 strain of the present invention.
- the results are presented as a percentage of the total populations of CD4 + / CD8 + in spleen a time intervals after vaccination and as a percentage of cells expressing IFN- ⁇ of the total population of CD4 + / CD8 + after stimulation with complete M. tuberculosis antigen. * denotes statistically significant differences between the groups at the indicated time points (p ⁇ 0.005).
- the results of cellular immunity show that the number of CD4 + lymphocytes in animals vaccinated with the SO2 strain is greater at days 14, 30, 45 and 60 and the production of specific IFN ⁇ against M. tuberculosis antigens is significant on days 45 and 60 with respect to mice vaccinated with BCG.
- the number of CD8 + lymphocytes in animals vaccinated with the SO2 strain is greater on days 45 and 60 and the production of specific IFN ⁇ against M. tuberculosis antigens is significant on day 14 with respect to mice vaccinated with BCG.
- Fig. 4 Protective efficacy of SO2 of the present invention compared to BCG in vaccinated Balb / c mice.
- the reduction of cfus in lung and spleen mice vaccinated with SO2 is similar to that obtained with those vaccinated with BCG and demonstrates significant protection with respect to unvaccinated mice.
- Fig. 5 Protective efficacy in guinea pigs vaccinated with the SO2 strain of the present invention and BCG against low doses of M. tuberculosis
- Fig. 6 Protective efficacy in guinea pigs vaccinated with the SO2 strain of the present invention and BCG against infection with high doses of M. tuberculosis H37Rv. a, Since the mouse and guinea pig protection experiments infected at low doses showed clear protection in mice vaccinated with SO2 and BCG but no differences between BCG and SO2, a guinea pig model with high dose infection was used.
- Guinea pig survival curve after aerosol infection with H37Rv of M. tuberculosis, b The extent of lung disease and disseminated infection, measured by total pulmonary consolidation. The values of each individual animal sacrificed at the human endpoint are indicated by an "x".
- the dashed line indicates the average value in percentage of the group (# in SO2 corresponds to two animals), c, low resolution (x30) of images of representative sections of pulmonary lobes taken from guinea pigs of each of the treatment groups.
- the bar represents 1 mm. d, Average cfu counts in the spleen and lungs of vaccinated and unvaccinated guinea pigs.
- FIG. 7 The attenuation of infection with SO2 of the present invention in a BaIbC mouse intravenously is not restored by complementing with phoP.
- Colony reduction (CFU) is observed in both spleen (7a spleen) and lung (7b lung), measured at 3 and 6 weeks.
- the cfus levels of the wild strain are not restored in the complemented strain.
- the SO2 strain of the present invention does not produce DIM and the synthesis of DIM is independent of the phoP mutation. Lipid analysis of different strains of M. tuberculosis by thin layer chromatography. 8 a DIM production can be observed in strain MT103 while strain SO2 and complementation with the phoP gene (SO2 pS05) do not produce DIM. This demonstrates that in SO2 the absence of DIM is independent of phoP. 8 b
- the strain MT103 and strain MT103 are shown inactivating only the phoP gene (MT103 AphoP / .hyg) and the 2 are capable of synthesizing DIM I confirming that the production of DIM is independent of the phoP mutation.
- Fig 11. Study of mouse attenuation: Survival curve of Balb / C mice inoculated by "intratracheal route" to study the attenuation of the different strains of M. tuberculosis. H37Rv and MT103 correspond to strains of M. tuberculosis without mutations and all mice die before 10 a week with the strain of M. tuberculosis DIM- (1A29) at 20 weeks 50% of the mice survive. All animals inoculated with SO2 (mutant phoP- and DIM-) survive the 20 weeks of the experiment. Fig. 12. Survival curve and guinea pig weight to study the toxicity of SO2, with 50 times the vaccine dose.
- Fig 13 Survival of vaccinated guinea pigs after infection with M. tuberculosis. Protection study in guinea pigs, survival at 300 days: Survival curve of unvaccinated guinea pigs (saline), vaccinated with the current BCG vaccine, with a strain of M. tuberculosis phoP- or with SO2 (mutant phoP- and DIM-) . After vaccination subcutaneously, the animals are infected with a strain of virulent M. tuberculosis (H37Rv) at a high dose to study survival. At 60 days the 6 unvaccinated guinea pigs die while the groups vaccinated with SO2, phoP- and BCG survive.
- H37Rv virulent M. tuberculosis
- One aspect of the present invention relates to an isolated microorganism belonging to the genus Mycobacter ⁇ um characterized in that it comprises the inactivation of the RvO757 gene that confers a PhoP- phenotype and the inactivation of a second gene that prevents the production of DIM (DIM- phenotype). Additionally, the present invention comprises the use of said microorganism for the elaboration of a vaccine for the prevention of tuberculosis as well as the vaccine per se.
- isolated strains of the genus Mycobacterium phoP-DIM- have characteristics that make them especially suitable for use as vaccines, both for the level of attenuation they acquire and for the level of protection they confer .
- mice were inoculated by aerosol with the SO2 strain (phoP-DIM-). Said mice survive (fig 2a) significantly more than mice infected by the wild strain. Additionally, this attenuation is complemented with phoP in the SO2 + pS05 strain (phoP + DIM-) (Fig. 8a).
- the levels of protection conferred by the M. tuberculosis strain of M. tuberculosis of the present invention and the BCG were similar in both the lungs and the spleen up to four weeks after the infection. If we compare the relative proportions of CD4 + and CD8 + cells of the spleens of vaccinated mice, in the mice vaccinated with the SO2 strain of the present invention a higher percentage of both CD4 + and CD8 + cells was found, compared with the mice vaccinated with BCG.
- tuberculosis depends in general on the generation of a cellular immune response of the THi type characterized by the secretion of IFN- ⁇ from the antigen-specific T cells, we can conclude that the relatively high levels of cell activation T induced by the SO2 strain of the present invention contributes to its ability to confer a potent protective response.
- guinea pigs were inoculated with a low dose of M. tuberculosis H37Rv, the levels of protection conferred by vaccination with the SO2 strain of the present invention and similar BCG in both the lungs and the spleen up to 4 weeks after the infection.
- Both vaccines provided extremely efficient protection, reducing the cfs in the lungs and spleens by approximately 2 log, compared to the control groups that received saline.
- there was no statistically significant difference between the two vaccine groups With such a short period after infection, we can assume that it would be difficult to demonstrate the greater efficacy of a new vaccine with respect to BCG.
- the results described in the present invention demonstrate that the SO2 strain and therefore a microorganism belonging to the Mycobacterium genus (particularly of the M. Tuberculosis complex) with phoP-DIM- phenotype, is a more effective vaccine than BCG according to a series of criteria. It is more attenuated than BCG in SCID mice, imparts to mice a protective immunity at least as good as BCG and generates more potent cellular immunity responses. Additionally, in protection experiments carried out in guinea pigs against a high-dose infection of H37Rv, the strain with DIM-phoP phenotype imparts 100% survival to guinea pigs in circumstances in which BCG only allows 33% survival.
- a first aspect of the present invention refers to an isolated microorganism belonging to the genus Mycobacter ⁇ um characterized in that it comprises inactivation or deletion: a. from the phoP gene or from one to more phoP gene regulatory genes or regulated by Phop and b. of a second gene that eliminates the production of DIM.
- the microorganism isolated from the invention is characterized in that the inactivation of the phoP gene is carried out by means of the inactivation or deletion of the RvO757 gene.
- the isolated microorganism of the invention is characterized in that the inactivation of the production of DIM is carried out by means of the deletion or inactivation of the Rv2930 gene (fadD26).
- the isolated microorganism of the invention is characterized by comprising the deletion or inactivation of the genes Rv2930 and RvO757.
- the microorganism isolated from the invention is characterized in that the species of the genus Mycobacterium belongs to the Mycobactarium tuberculosis complex.
- a second aspect of the invention refers to the process of manufacturing the isolated microorganism of the invention comprising:
- the inactivation or deletion of the phoP gene or one or more regulatory genes of the phoP gene preferably the inactivation or deletion of the RvO757 gene and b.
- the inactivation or deletion of a second gene that eliminates the production of DIM preferably the deletion or inactivation of the gene Rv2930 ⁇ fadD26
- a third aspect of the invention relates to a vaccine (hereinafter vaccine of the invention) to immunize an individual against the symptoms caused by tuberculosis, wherein said vaccine comprises at least one microorganism isolated from the invention.
- the vaccine also comprises pharmacologically acceptable excipients.
- a fourth aspect of the invention relates to the process of preparing a medicament, preferably a vaccine, which comprises the incorporation of an isolated microorganism of the invention in a therapeutically effective dose to a medium suitable for human or animal administration and, optionally, adding pharmacologically suitable excipients for the manufacture of vaccines.
- Said medication is suitable for the treatment of bladder cancer, for the treatment or prevention of tuberculosis, or as a vector or adjuvant.
- Said medication is suitable for the treatment of bladder cancer, for the treatment or prevention of tuberculosis, or as a vector or adjuvant.
- a fifth aspect of the invention refers to the use of the isolated microorganism of the invention, for the elaboration of the vaccine of the invention, for the prevention and / or treatment of human or animal tuberculosis.
- Western blot analysis was performed following normal procedures. As secondary antibodies, goat anti-rabbit antibodies labeled with horseradish peroxidase (Bio-Rad Laboratories, Hercules, CA) were used.
- tuberculosis in order to provide an approximate absorption of 20 viable bacilli within the lungs.
- Ten mice were used for each experimental group.
- groups of 7 mice were infected with 200 Dl of PBS containing doses equivalent to 2 x10 5 , 2 x10 4 and 2 x10 3 of viable BCG and 5.4 x 10 6 , 5.4 x 10 5 and 5.4 x 10 4 of The viable M. tuberculosis phoP strain through a lateral vein of the tail.
- the significance in the differences in survival times among treated mice was determined with the use of the Mantel-Haenszel test.
- Feasibility counts were made in serial dilutions of the homogenate, placing on Middlebrook 7H11 + OADC agar and examining its growth after 3 weeks.
- the tissues were fixed in formalin buffered saline and fixed in paraffin. Five Dm thick sections were cut, colored with Ziehl-Neelsen dye.
- Invitrogen Corporation containing 0.5 mg / ml type 2 collagenase (Worthington, NJ, USA) , and 2U / ml of DNAase (GIBCO), incubating for 1 hour at 37 ° C, with 5% CO2. They were then passed through a 70 ⁇ m cell sieve (Falcon, Becton Dickinson 70 ⁇ m Nylon 35-2350), crushed with the piston of a syringe and rinsed with medium. The cells were centrifuged, the supernatant was removed and the red blood cells were removed with lysis buffer [26].
- the cells were resuspended in FACS buffer (1X PBS, pH 7.2, 1% BSA), and counted.
- FACS buffer (1X PBS, pH 7.2, 1% BSA
- the marking of the cell surface was carried out through incubation of 10 6 cells with 100 ⁇ l of monoclonal antibodies against CD4-FITC or CD8-FITC, diluted at a ratio of 1: 20 in PBS containing 1% of BSA and 0, 1% sodium azide for 20 min at 4 o C, analyzed with a FACScan cytometer.
- the strain M. tuberculosis H37Rv was grown in Middlebrook 7H9 medium
- the cells and the culture medium were centrifuged, the supernatant was discarded and, after counting and checking the viability, 2.5x10 5 cells per tube were labeled on the surface of the CD4 + or CD8 + cells as described above. After washing, the cells were resuspended and incubated for 20 min at 4 o C in 0.1% saponin dissolved in PBS. Intracellular IFN- ⁇ was detected by incubation of the cell for 20 min at 4 o C in the dark, with 100 ⁇ l of a 1/20 dilution of monoclonal anti-IFN- ⁇ labeled with phycoerythrin (PE). The cells were fixed with 100 ⁇ l of 4% paraformaldehyde diluted in PBS. Samples were analyzed at 20 minutes with a FACScan cytometer. The isotype controls were Ab-FITC (1: 20 dilution) + Ab-PE (1: 20 dilution).
- mice 1.4.- Protective efficacy of SO2 of the present invention in Balb / c mice. All animals were kept under controlled conditions in the P3 High Security Laboratory of the Animal Installation of the Pasteur Institute in Paris, in accordance with the directives of the European Union for the protection of experimental animals. Groups of Balb / c mice (7 per group) were vaccinated subcutaneously at the base of the tail with 10 7 cfus of the SO2 strain of the present invention or BCG (Pasteur). At 8 weeks after vaccination, 2.5 x 10 5 cfu of M. tuberculosis H37Rv were applied to all mice intravenously. Four weeks after the injection, the mice were sacrificed.
- Viability counts were made in serial dilutions of the homogenate, grown in Middlebrook 7H11 broth + OADC agar, examining at 3 weeks the growth of M. tuberculosis H37Rv, of the SO2 strain of the present invention based on the kanamycin resistance phenotype of this second strain.
- Spleen and lung tissue were aseptically removed left and middle, right middle lobe and right caudal lobes), being placed in sterile containers.
- the material was stored at - 20 ° C, then processed in order to count the number of bacteria.
- the tissues were homogenized in 10 ml (lung) or 5 ml (spleen) of sterile deionized water, with the use of a rotary blade macerator system (Ystral). Viable cell counts were performed in serial dilutions of the homogenate, grown in Middlebrook 7H11 + OADC agar, the growth of M. tuberculosis was examined at 3 weeks. The data were transformed into log- ⁇ 0 for analysis and the viable M. tuberculosis numbers of each vaccine group were compared with the control group with saline solution by Student's "t" test.
- Post-mortem collection and treatment of the samples were performed as described above, except that the pulmonary consolidation was measured with the use of image analysis of sections of lung tissue fixed in formalin, colored with Hematoxyline and Eosin (H + E).
- the survival of the animals was compared with the use of Kaplan Meier survival calculations, using the Log Rank distribution analysis to identify statistically significant differences.
- Data on cfu and consolidation of lesions were analyzed by ANOVA, with the use of Fishers pair comparisons, in order to compare the average values of the groups.
- Example 3 Survival of mice infected with the strains of the present invention and BCG.
- the attenuation of the SO2 strain was also compared with the BCG in SCID mice after intravenous administration.
- Groups of SCID mice were inoculated with a series of doses (2 x10 5 , 2 x10 4 and 2 x10 3 cfu) of BCG Pasteur or of the SO2 strain (5.4 x 10 6 , 5.4 x 10 5 and 5 ., x 10 4 cfu) through a lateral vein of the tail.
- the histological staining of infected alveolar macrophages of a subgroup of mice sacrificed three weeks after the infection revealed a lower number of alcohol resistant acid bacilli in the lungs of mice infected with the SO2 strain of M.
- spleen cell suspensions were collected from groups of at least four Balb / c mice vaccinated subcutaneously with the SO2 strain of the present invention and BCG Phipps, the relative proportions of CD4 + and CD8 + cells being determined by cytofluorometry (Fig. 3).
- Vaccination with SO2 induced a significantly higher number of CD4 + cells 14 days after vaccination, compared with BCG vaccination, and a significantly higher number superior of CD8 + cells after 45 days.
- These splenocytes were stimulated with total antigens derived from culture filtrate of M. tuberculosis.
- lymphocyte populations were analyzed by flow cytometry, combining specific antibodies for the detection of CD4 + / CD8 + cells and intracellular synthesis of IFN-D.
- Vaccination with SO2 induced a significantly higher proportion of CD4 + / IFN-D + producing cells 45 days after vaccination, compared with BCG (Fig. 3). From a certain point in time, the proportion of cells that produced CD8 + / IFN-D + was always higher in the SO2 group (significantly different on day 14).
- Example 5 Protective immunity generated by SO2 of the present invention in Balb / c mice.
- mice vaccination experiments indicated that the attenuation of the SO2 strain of the present invention gave vaccine characteristics similar to BCG Pasteur.
- guinea pigs constitute a more relevant model of human tuberculosis, with many similarities regarding the progress and pathology of the disease.
- this animal model is a more appropriate system to evaluate the efficacy of a vaccine.
- the animals that received the lower dose were sacrificed at 4 weeks, counting the bacterial loads in the lungs and spleens.
- Protective efficacy was determined by comparing the numbers of viable M. tuberculosis H37Rv recovered from guinea pig organs in each treatment group. In this experiment, the reduction of cfus in lungs and spleens was significantly different between the unvaccinated control animals and those vaccinated with BCG or SO2 of M. tuberculosis
- the guinea pigs who received the high dose were sacrificed 180 days after application or when 20% loss of body weight was observed. Protection levels were determined by comparing the Survival times of the guinea pigs of each treatment group. The progress of lesion development was also studied in vaccinated / infected guinea pigs, compared with that observed in unvaccinated / infected animals. During the phase of the post-inhalation experiment, all unvaccinated guinea pigs and four of the guinea pigs vaccinated with BCG were sacrificed at the human endpoint, before the endpoint of time (180 days) due to severe and progressive disease (Fig. 6a).
- the guinea pigs vaccinated with the SO2 strain of the present invention survived during the study.
- the guinea pigs vaccinated with the SO2 strain gained weight and did not show any visible or clinical signs of disease.
- Example 7 Attenuation of SO2 of the present invention is due to the double PhoP-DIM- mutation.
- Example 8 Protection of SO2 of the present invention is due to the double PhoP-DIM- mutation.
- the protection in vaccinated guinea pigs and infected by aerosol with M. tuberculosis H37Rv was studied. Survival in guinea pigs at 300 days. After vaccination by subcutaneous route, the animals are infected with a strain of virulent M. tuberculosis (H37Rv) with a high dose to study survival. At 60 days the 6 unvaccinated guinea pigs die while the groups vaccinated with S02, phoP- and BCG survive.
- Example 9 Construction of the vaccine candidate against tuberculosis based on the mutation by deletion of the fadD26 gene
- the M. tuberculosis strains used for the construction of the mutant by deletion of the fadD26 gene are SO2, which contains the inactivated phoP gene by insertion of a kanamycin resistance cassette, and the clinical strain MT103.
- fadD26 Cloning of the fadD26 gene, involved in the synthesis of DIM.
- the fadD26 gene was amplified by PCR, from genomic DNA of M. tuberculosis H37Rv using primers fadD26Fw (SEQ ID NO: 1) and fadD26Rv (SEQ ID NO: 2).
- the PCR product was inserted into the pGEM-T Easy vector (Promega), to construct plasmid pAZ1.
- Plasmid pAZ3 was digested with Xho ⁇ releasing the insert fadD26 :: ⁇ hyg that was incorporated into the vector pJQ200X, linearized with the same enzyme. The final plasmid was named pAZ5.
- Plasmid pAZ5 was introduced into strains of M. tuberculosis SO2 and MT103.
- plasmid pWM19 which contains the ⁇ resolvase, is introduced and selected for resistance to gentamicin. Subsequently, the plasmid is removed by incubating 39
- the phoP gene was amplified by PCR, from genomic DNA of M. tuberculosis H37Rv using the phoPF primers (SEQ ID NO: 3) and phoPR (SEQ ID NO: 4). The PCR product was inserted into the pGEM-T Easy vector (Promega), to construct plasmid pAZ11.
- Plasmid pAZ13 was digested with Xho ⁇ releasing the phoPv. ⁇ km insert that was incorporated into the linear vector pJQ200X raised with the same enzyme. The final plasmid was named pAZ15.
- Plasmid pAZ15 will be introduced into the strain of M. tuberculosis MT103 AfadD26.
- Selection of simple recombinants Kanamycin culture (20 ⁇ g / ml) of the bacteria that have incorporated the plasmid and verification for its resistance to gentamicin (10 ⁇ g / ml).
- plasmid pWM19 which contains the ⁇ resolvase, will be introduced and selected for hygromycin resistance (20 ⁇ g / ml). Subsequently, the plasmid will be removed by incubating at 39 0 C in 2% sucrose (Malaga e ⁇ al. 2003).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES07730491T ES2433518T3 (es) | 2006-03-24 | 2007-03-14 | Vacuna contra la tuberculosis |
CN2007800103665A CN101405386B (zh) | 2006-03-24 | 2007-03-14 | 肺结核疫苗 |
CA2647287A CA2647287C (en) | 2006-03-24 | 2007-03-14 | Mycobacterium tuberculosis complex with inactivated phop and without dim production for tuberculosis vaccine |
US12/294,199 US8287886B2 (en) | 2006-03-24 | 2007-03-14 | Tuberculosis vaccine |
EP07730491.3A EP1997881B1 (en) | 2006-03-24 | 2007-03-14 | Tuberculosis vaccine |
BRPI0709106A BRPI0709106B8 (pt) | 2006-03-24 | 2007-03-14 | vacina contra tuberculose |
JP2009500878A JP5324420B2 (ja) | 2006-03-24 | 2007-03-14 | 結核ワクチン |
US13/619,615 US8642011B2 (en) | 2006-03-24 | 2012-09-14 | Tuberculosis vaccine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ESP200600761 | 2006-03-24 | ||
ES200600761 | 2006-03-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/294,199 A-371-Of-International US8287886B2 (en) | 2006-03-24 | 2007-03-14 | Tuberculosis vaccine |
US13/619,615 Continuation US8642011B2 (en) | 2006-03-24 | 2012-09-14 | Tuberculosis vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007110462A1 true WO2007110462A1 (es) | 2007-10-04 |
Family
ID=38540819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2007/070051 WO2007110462A1 (es) | 2006-03-24 | 2007-03-14 | Vacuna contra la tuberculosis |
Country Status (10)
Country | Link |
---|---|
US (2) | US8287886B2 (es) |
EP (1) | EP1997881B1 (es) |
JP (1) | JP5324420B2 (es) |
CN (1) | CN101405386B (es) |
BR (1) | BRPI0709106B8 (es) |
CA (1) | CA2647287C (es) |
ES (1) | ES2433518T3 (es) |
PT (1) | PT1997881E (es) |
RU (1) | RU2443773C2 (es) |
WO (1) | WO2007110462A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011130878A1 (en) * | 2010-04-22 | 2011-10-27 | Shenzhen Christyins Biosciences Ltd. | Tuberculosis vaccines including recombinant bcg strains overexpressing phop, and/or phop regulon protein(s) |
RU2468816C1 (ru) * | 2011-06-23 | 2012-12-10 | Елена Александровна Шмелева | Пробиотический бактериальный препарат корпускулярных антигенов коринебактерий липопептидополисахаридной природы для профилактики и лечения туберкулеза, способ его получения |
JP7035063B2 (ja) * | 2017-04-07 | 2022-03-14 | ジュン・リウ | phoP-phoRを過剰発現する組換えBCG |
EP4233912A3 (en) | 2018-02-19 | 2023-11-01 | Universidad De Zaragoza | Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients |
EP3797791A1 (en) * | 2019-09-26 | 2021-03-31 | Universidad De Zaragoza | Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003012075A1 (es) * | 2001-07-31 | 2003-02-13 | Universidad De Zaragoza | DISMINUCIÓN DE VIRULENCIA DE MYCOBACTERIUM TUBERCULOSIS Y PROTECCIÓN CONTRA LA TUBERCULOSIS POR LA INACTIVACIÓN DEL GEN phoP |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2153354C1 (ru) * | 1999-03-31 | 2000-07-27 | Московский городской научно-практический центр борьбы с туберкулезом | Вакцина против туберкулеза |
CN1339583A (zh) * | 2001-09-28 | 2002-03-13 | 靳凤烁 | 重组耻垢分支杆菌其制备及在治疗膀胱肿瘤药物中的应用 |
-
2007
- 2007-03-14 CN CN2007800103665A patent/CN101405386B/zh active Active
- 2007-03-14 RU RU2008142140/10A patent/RU2443773C2/ru active
- 2007-03-14 BR BRPI0709106A patent/BRPI0709106B8/pt active IP Right Grant
- 2007-03-14 CA CA2647287A patent/CA2647287C/en active Active
- 2007-03-14 US US12/294,199 patent/US8287886B2/en active Active
- 2007-03-14 PT PT77304913T patent/PT1997881E/pt unknown
- 2007-03-14 WO PCT/ES2007/070051 patent/WO2007110462A1/es active Application Filing
- 2007-03-14 ES ES07730491T patent/ES2433518T3/es active Active
- 2007-03-14 EP EP07730491.3A patent/EP1997881B1/en active Active
- 2007-03-14 JP JP2009500878A patent/JP5324420B2/ja active Active
-
2012
- 2012-09-14 US US13/619,615 patent/US8642011B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003012075A1 (es) * | 2001-07-31 | 2003-02-13 | Universidad De Zaragoza | DISMINUCIÓN DE VIRULENCIA DE MYCOBACTERIUM TUBERCULOSIS Y PROTECCIÓN CONTRA LA TUBERCULOSIS POR LA INACTIVACIÓN DEL GEN phoP |
Non-Patent Citations (51)
Also Published As
Publication number | Publication date |
---|---|
CN101405386B (zh) | 2013-02-13 |
US20100129407A1 (en) | 2010-05-27 |
EP1997881A4 (en) | 2010-01-13 |
BRPI0709106B1 (pt) | 2020-05-19 |
EP1997881B1 (en) | 2013-09-25 |
ES2433518T3 (es) | 2013-12-11 |
US8642011B2 (en) | 2014-02-04 |
CA2647287A1 (en) | 2007-10-04 |
RU2008142140A (ru) | 2010-04-27 |
BRPI0709106B8 (pt) | 2021-05-25 |
CA2647287C (en) | 2017-12-19 |
JP5324420B2 (ja) | 2013-10-23 |
RU2443773C2 (ru) | 2012-02-27 |
US20130022638A1 (en) | 2013-01-24 |
EP1997881A1 (en) | 2008-12-03 |
US8287886B2 (en) | 2012-10-16 |
JP2009529901A (ja) | 2009-08-27 |
BRPI0709106A2 (pt) | 2011-06-28 |
CN101405386A (zh) | 2009-04-08 |
PT1997881E (pt) | 2013-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Martin et al. | The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs | |
ES2366622T3 (es) | Cepas de bcg recombinante con capacidad potenciada para escapar del endosoma. | |
US7625572B2 (en) | Transformed bacterium lacking selectable marker and overexpression of antigens in mycobacteria | |
US8124068B2 (en) | Recombinant intracellular pathogen immunogenic compositions and methods of use | |
US7829104B2 (en) | Electroporation of Mycobacterium and overexpression of antigens in mycobacteria | |
RU2760580C2 (ru) | РЕКОМБИНАНТНАЯ BCG, СВЕРХЭКСПРЕССИРУЮЩАЯ PhoP-PhoR | |
US8642011B2 (en) | Tuberculosis vaccine | |
CA2293826A1 (en) | Attenuated recombinant mycobacteria useful as immunogens or as vaccine components | |
US7722861B2 (en) | Attenuated Mycobacterium tuberculosis vaccines | |
AU2019221709B2 (en) | Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients | |
Titball et al. | Attenuated Bacterial Vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07730491 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009500878 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780010366.5 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2647287 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8123/DELNP/2008 Country of ref document: IN Ref document number: 2007730491 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008142140 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12294199 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0709106 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080923 |